

MedX Health (MDX - V)

Netherlands Provides Investors a Blueprint for Understanding Significant Recurring Revenue Potential

December 15, 2020

Doug Cooper, MBA

(416) 643 - 3863

dcooper@beaconsecurities.ca

- MedX announced that it has begun the rollout of its technology package (hardware and software) in the Netherlands.
- Through its Dutch partner, IVPG (www.ivpg.nl), MedX has installed its SIAScope hardware and DermSecure software platform in 2 clinics and expects to be installed in 3 more by the end of the year.
- Even after only a month, the company has provided real-time data as per the patient uptake. In particular, over 800 assessments on 500 patients have been performed. **This equates to ~20 assessments per day per clinic.** As a reminder, MDX receives ~\$10 per assessment, which creates a very profitable recurring revenue stream.
- We believe there are some very important investment considerations from today's announcement:
 - a) The Netherlands is ranked 5th in the world in terms of melanoma skin cancer. In fact, over 50% of all reported cancers in the country are skin cancer;
 - b) The Dutch government has deemed that the current standard of care for skin cancer prevention is not working;
 - c) The choice of MedX's skin cancer assessment technology shows its efficacy.
- **With the early success in just its initial 2 clinics, IVPG has indicated it plans to roll-out the technology platform to 41 clinics over the next 12-18 months.**
- We believe investors should understand the recurring, high margin, revenue juggernaut that is in the midst of being created. Given the metrics already apparent after just one month at the 2 installed clinics, 41 clinics would represent ~\$3 million of recurring revenue (ie. 41 x 312 days x 20 scans x \$10).
- The Netherlands represents but the first of many country roll-outs that includes Brazil, Mexico, Canada and the United States. **Today's announcement provides investors a blueprint to understand the substantial operating leverage and earnings power inherent in MDX's recurring revenue model.**
- Note that all countries face similar skin cancer prevention issues (ie. difficulty in early detection and long wait times to see a dermatologist). **MedX's platform has proven to be very effective at early detection, which is a win-win for patients and payors.** As such, we anticipate future announcements could include clinic partnerships (ie. pharmacies, health clinics, etc) in countries around the world. With a population of 17 million and \$3 million of recurring revenue from only 41 clinics, we believe the Netherlands' announcement is very important but may ultimately represent a relatively small revenue contributor.
- From a valuation perspective, with a market cap of ~\$20 million and a model that is starting to demonstrate significant traction, **MedX trades at a fraction of other tele-health/recurring revenue technology companies.**
- We maintain our Buy recommendation and \$0.45 target price.

Roll-Out in the Netherlands

Buy (unch) \$0.45 (unch)

Recent/Closing Price	\$0.12
12-month Target Price	\$0.45
Potential Return	291%
52 Week Price Range	\$0.07 - \$0.16

Estimates

YE: Dec 31	FY20E	FY21E
Revenue (\$MM)	0.5	14.9
EBITDA (\$MM)	-2.3	5.2
EPS	-0.01	0.02

Valuation

	FY20E	FY21E
EV/Sales	40.3x	1.4x
EV/EBITDA	-9.0x	3.9x
P/E	-11.9x	5.2x

Stock Data (MM except per Share items)


Shares Outstanding	
Basic	175.4
FD	175.4
Market Cap	
Basic	\$20.2
FD	\$20.2
Net Debt	\$0.0
EV	\$20.2

About the Company

MedX's mission is to develop and implement non-invasive, practical, drug free and cost-effective skin analysis and assessment systems for use by trained medical professionals. The company's Class 2 skin cancer scanning device with images that can be uploaded on its proprietary cloud-based tele-health platform are sent to local dermatologists for review. MedX is through its R&D phase with regulatory approval in 35 countries and has firmly commenced commercialization.

All prices in C\$ unless otherwise stated

Stock Performance



Disclosure Requirements

Does Beacon, or its affiliates or analysts collectively, beneficially own 1% or more of any class of the issuer's equity securities? Yes No

Does the analyst who prepared this research report have a position, either long or short, in any of the issuer's securities? Yes No

Has any director, partner, or officer of Beacon Securities, or the analyst involved in the preparation of the research report, received remuneration for any services provided to the securities issuer during the preceding 12 months? Yes No

Has Beacon Securities performed investment banking services in the past 12 months and received compensation for investment banking services for this issuer in the past 12 months? Yes No

Was the analyst who prepared this research report compensated from revenues generated solely by the Beacon Securities Investment Banking Department? Yes No

Does any director, officer, or employee of Beacon Securities serve as a director, officer, or in any advisory capacity to the issuer? Yes No

Are there any material conflicts of interest with Beacon Securities or the analyst who prepared the report and the issuer? Yes No

Is Beacon Securities a market maker in the equity of the issuer? Yes No

This report makes reference to a recent analyst visit to the head office of the issuer or a site visit to an issuer's operation(s)? Yes No

Did the issuer pay for or reimburse the analyst for the travel expenses? Yes No

Beacon analysts are not permitted to own the securities they cover, but are permitted to have a position, either long or short, in securities covered by other members of the research team, subject to blackout conditions.

All information contained herein has been collected and compiled by Beacon Securities Limited, an independently owned and operated member of the Investment Industry Regulatory Organization of Canada (IIROC). All facts and statistical data have been obtained or ascertained from sources, which we believe to be reliable, but are not warranted as accurate or complete.

All projections and estimates are the expressed opinion of Beacon Securities Limited, and are subject to change without notice. Beacon Securities Limited takes no responsibility for any errors or omissions contained herein, and accepts no legal responsibility from any losses resulting from investment decisions based on the content of this report.

This report is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell securities discussed herein. Based on their volatility, income structure, or eligibility for sale, the securities mentioned herein may not be suitable or available for all investors in all countries.

As at November 30th, 2020	#Stocks	Distribution
BUY	57	67.1%
Speculative Buy	18	21.2%
Hold	0	0.0%
Sell	0	0.0%
Under Review	9	10.6%
Tender	1	1.2%
Total	85	100%

BUY Total 12-month return expected to be > 15%
 Speculative Buy Potential 12-month return is high (>15%) but given elevated risk, investment could result in a material loss
 Hold Total 12-month return is expected to be between 0% and 15%
 Sell Total 12-month return is expected to be negative
 Under Review
 Tender Clients are advised to tender their shares to a takeover bid or similar offer

Dissemination

Beacon Securities distributes its research products simultaneously, via email, to its authorized client base. All research is then available on www.beaconsecurities.ca via login and password.

Analyst Certification

The Beacon Securities Analyst named on the report hereby certifies that the recommendations and/or opinions expressed herein accurately reflect such research analyst's personal views about the company and securities that are the subject of the report; or any other companies mentioned in the report that are also covered by the named analyst. In addition, no part of the research analyst's compensation is, or will be, directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report.